Back to Acceleration Radar
IARTIntegra LifeSciences Holdings
Health Care · Medical/Dental Instruments · Small
$11.91−3.37%
As of 23 Oct 2026Mkt cap $1.3B
Stage 13
AVOID
Fundamentals
8.1/75
Technical
3.0/15
Independent
11.1/90
GCAE viewFundamental /75 is below the Stage 13 acceptable-business floor
Price
- 1M
- −25.0%
- 3M
- −39.0%
- 6M
- +12.7%
- 1Y
- −23.0%
Financials & valuation
Cached filing evidence · as of 2026-10-23
Valuation
- P/E
- 70.1xHist median 87.7x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 10.6x
- FCF yield
- 9.4%
Quality
- ROIC
- —
- Operating margin
- 1.8%
- FCF margin
- -1.9%
- Current ratio
- 2.5x
Growth
- Revenue growth
- +1.5%Latest FY YoY
- Revenue CAGR
- +1.5%
- EPS CAGR
- —
- FCF CAGR
- —
Capital
- Share-count trend
- −2.3%3Y annualised
- Net debt
- $669M13.3x OCF
Annual trend
- CAGR 2021–2025
- +1.5%
- Latest · 2025
- $2B
- YoY
- +1.5%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
Fundamental /75 is below the Stage 13 acceptable-business floor
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
More details & evidence
Production decision
- Stage 13
- AVOID
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-23
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded